Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Wednesday, February 4, 2015

Gilead to discount its pricey Sovaldi drug

LOS ANGELES (MarketWatch)—The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.

So why was Gilead’s GILD, -7.92%  stock down by double digits at one point Wednesday morning? The main driver of those results, the hit hepatitis C drug Sovaldi, will come down in price, the company says.

Gilead will begin offering discounts and rebates of up to 46% this year for the $1,000-a-day pill to insurers and others who pay for health care expenses, now that rivals like AbbVie Inc. ABBV, -6.73%  and Merck & Co. Inc. MRK, -2.90%  are entering the market.

Read more...
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)